The anti-HIgG(Fc)Fab-N-DM1 ADC represents a novel class of antibody-drug conjugates (ADCs) designed for targeted cancer therapy. This ADC utilizes an anti-HIgG(Fc) antibody fragment (Fab) linked to the cytotoxic agent DM1, a potent microtubule inhibitor. By specifically targeting the Fc region of human immunoglobulin G (IgG), the anti-HIgG(Fc)Fab-N-DM1 ADC selectively delivers the cytotoxic payload to tumor cells exhibiting Fc receptors, minimizing off-target effects and enhancing therapeutic efficacy. This targeted approach holds promise for improving outcomes in patients with Fc receptor-expressing tumors, illustrating the potential of precision medicine in oncology.